Drug Trial Radar · NCT07417670
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Oct 4, 2024
Primary completion
Aug 12, 2025
Study completion Aug 18, 2025
Sponsor
- Lead sponsor
- Carnot LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to evaluate satisfaction with the use of orodispersible Memantine (OD) versus conventional Memantine tablets (MTb) using the validate SATMED-Q in patients with moderate to severe Alzheimer's disease. Due to the neurocognitive impairment associated with these stages of the disease, treatment satisfaction will be assessed indirectly through the primary caregiver. The main questions this study seeks to answer are: * Is caregiver satisfaction higher with OD (Sinolvir®) compared with MTb? * What adverse events or side effects occur in patients receiving memantine in either pharmaceutical form? Researchers will compare OD (Sinolvir®) and MTb to identify differences in caregiver satisfaction and to describe the adverse events reported. Satisfaction will be evaluated across the six domains of the SATMED-Q questionnaire, and results will be summarized by domain and by pharmaceutical dosage form. All adverse events reported during the study will be documented. Participants will receive Sinolvir®(OD) or Eutebrol® (MTb) daily, according to dosing regimens determined by the treating physicians based on the approved prescribing information. The duration of participation will be two months. After two months of treatment, eligible primary caregivers will complete the SATMED-Q questionnaire. Caregivers will be invited to participate at Visit 1 and will complete the satisfaction questionnaire at Visit 2, which will be conducted between days 60 and 70 after Visit 1.
Conditions
- Alzheimer Disease
Interventions
MemantineDrug
orodispersible memantine administered according to a dose titration schedule.
Memantine Oral TabletDrug
Conventional memantine tablets administered according to a dose titration schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Caregiver treatment satisfaction assessed by the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q)Time frame: Between Day 71 and Day 80 after treatment initiation.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital Ángeles del Pedregal
Mexico City, Mexico
Private Practice
Saltillo, Coahuila, Mexico
Private Geriatrics Practice
Guadalajara, Jalisco, Mexico
Private Practice
Monterrey, Nuevo León, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.